Rbin-1 (also known as ribozinoindole-1) is a potent and specific chemical inhibitor of eukaryotic ribosome assembly.

GeA-69 (GeA69) is a novel, potent and selective allosteric inhibitor of poly-adenosine-diphosphate-ribose polymerase 14 (PARP14) targeting macrodomain 2, with a Kd of 2.1 µM.

RBN-012759 is a novel, potent and selective inhibitor of PARP14.

Rucaparib (formerly AG-014699 or PF-01367338; trade name: Rubraca) is a potent, tricyclic indole based, and orally bioavailable inhibitor of PARP (poly(ADP-Ribose) polymerase) with potential anticancer activity.

Rucaparib CAMSYLATE (AG014699; AG14447; PF01367338; trade name: Rubraca), the CAMSYLATE salt of rucaparib, is a potent PARP inhibitor approved by FDA for the treatment of ovarian cancer.

NMS-P118 is a novel potent, orally available, and highly selective PARP-1 (protein poly(ADP-ribose) polymerase-1) inhibitor with 150-fold selectivity for PARP-1 over PARP-2 (Kd 0.009 μM vs 1.39 μM, respectively).

Olaparib (formerly also known as AZD-2281; KU-59436; KU0059436; trade name Lynparza) is a potent, novel and orally bioavailable small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential anticancer activity.

SRT2183 (SRT 2183; SRT-2183) is a novel and potent small-molecule activator of the sirtuin subtype1-(SIRT1, EC50 =0.36 μM) developed by Sirtris Pharmaceuticals as therapeutics for the treatment of type 2 diabetes and potentially leukemia as well. SRT2183 has similar activity in the body to another SIRT1 activator SRT1720, but is closer in potency to resveratrol. […]

CeMMEC1, an N-methylisoquinolinone analog, is a novel and potent inhibitor of TAF4 with anticancer activity.

MN-64 is a potent and selective inhibitor of Tankyrase 1 and 2 (IC50 = 6 and 72 nM, respectively).